Clinical Trial Update: A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II study of ixabepilone plus cetuximab as first-line therapy for metastatic pancreatic cancer has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Ixempra (ixabepilone)

Snippet

Sponsor: R-Pharm | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2010-10-19